Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Clin Pharm Ther ; 44(6): 974-976, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31423611

RESUMO

WHAT IS KNOWN AND OBJECTIVE: Paclitaxel (Taxol) is an antineoplastic agent approved in the United States for the treatment of lung, breast, cervical, pancreatic cancers and Kaposi sarcoma. Paclitaxel does not cross the blood brain barrier, so central nervous system adverse effects are uncommon. CASE DESCRIPTION: We describe a 60-year-old woman with Stage IIIa squamous cell carcinoma of the left lung, who developed a generalized tonic-clonic seizure during her first infusion of paclitaxel. WHAT IS NEW AND CONCLUSION: Seizure related to a hypersensitivity reaction from paclitaxel infusion are rare but could be life-threatening and require immediate recognition, treatment and exclusion of other possible aetiologies.


Assuntos
Paclitaxel/efeitos adversos , Convulsões/induzido quimicamente , Barreira Hematoencefálica/metabolismo , Sistema Nervoso Central/diagnóstico por imagem , Feminino , Humanos , Pessoa de Meia-Idade , Convulsões/metabolismo
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa